<SEC-DOCUMENT>0001193125-13-210976.txt : 20130509
<SEC-HEADER>0001193125-13-210976.hdr.sgml : 20130509
<ACCEPTANCE-DATETIME>20130509160517
ACCESSION NUMBER:		0001193125-13-210976
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130509
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130509
DATE AS OF CHANGE:		20130509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD RESEARCH CORP
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21898
		FILM NUMBER:		13828650

	BUSINESS ADDRESS:	
		STREET 1:		225 SOUTH LAKE AVENUE
		STREET 2:		SUITE 1050
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101
		BUSINESS PHONE:		626-304-3400

	MAIL ADDRESS:	
		STREET 1:		225 SOUTH LAKE AVENUE
		STREET 2:		SUITE 1050
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d536117d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(D) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>OF THE SECURITIES EXCHANGE ACT OF 1934
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): May&nbsp;9, 2013 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Arrowhead Research Corporation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="31%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-21898</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>46-0408024</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>225 South Lake Avenue, Suite 1050, Pasadena, CA 91101 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code (626)&nbsp;304-3400 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4 (c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.02 Results of Operations and Financial Condition </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;9, 2013, Arrowhead Research Corporation announced and commented on its fiscal 2013 second quarter financial results for the period ended
March&nbsp;31, 2013. A copy of the press release is furnished herewith as Exhibit&nbsp;99.1. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>In accordance with General Instruction B.2 of
Form 8-K, the information in this Current Report on Form 8-K, including Exhibit&nbsp;99.1, shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or
otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly
set forth by specific reference in such filing to this Current Report on Form 8-K. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits.
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)&nbsp;Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated May 9, 2013.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: May&nbsp;9, 2013 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">ARROWHEAD RESEARCH CORPORATION</FONT></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kenneth Myszkowski</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kenneth Myszkowski</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d536117dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g536117g79a24.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRESS RELEASE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;9, 2013 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Arrowhead Reports Fiscal 2013 Second Quarter Financial
Results </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- Conference Call Today at 4:30 p.m. Eastern Time </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">PASADENA, Calif. &#151; May&nbsp;9, 2013 &#151; Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2013 second quarter ended
March&nbsp;31, 2013. The company is hosting a conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss results. To participate, please dial 877-317-6789 (toll free from the US), 866-605-3852 (toll free from Canada), or
412-317-6789 (for international callers). Investors may also access a live audio webcast of this conference call on the Company&#146;s website at <U>http://www.arrowheadresearch.com/presentations</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;During the last few months, Arrowhead has made important advances in our ARC-520 candidate against hepatitis B virus, our DPC siRNA delivery
system, and as a company we have been very active engaging with the investment community,&#148; said Dr.&nbsp;Christopher Anzalone, President and Chief Executive Officer. &#147;After our recently announced $36 million financing, led by RA Capital
with a syndicate of high-quality healthcare investment funds, we now have the resources to reach several important milestones and critical data points.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Fiscal 2013 Second Quarter and Recent Company Highlights </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Program and Pipeline Highlights </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Published a paper in the journal <I>Molecular Therapy</I> detailing the non-clinical development of ARC-520, including key data demonstrating a new way
of treating chronic hepatitis B virus infection by silencing the entire HBV genome; </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reported on a study of ARC-520 in a chimpanzee chronically infected with HBV, demonstrating that a low dose led to a 95% reduction in circulating viral
DNA and approximately 90% reductions in hepatitis e-antigen and s-antigen; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hosted an analyst and investor event in New York City, to discuss our hepatitis B program. Panel members for the event included company management and
key opinion leaders in HBV: Dr.&nbsp;Robert Gish, noted hepatologist and Arrowhead Clinical Advisory Board Chairman; and Joan Block, Executive Director and Co-founder of the Hepatitis B Foundation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Received two additional patents on the DPC siRNA delivery system; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Presented advancements being made by the company at multiple scientific and investor conferences, including the annual Needham Healthcare Conference
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Made progress towards completing the final steps required to file a regulatory submission during this quarter for first-in-man studies of ARC-520;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial Highlights </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closed $36 million offering of common and preferred stock. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Selected Fiscal 2013 Second Quarter Financial Results </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses for the
three months ended March&nbsp;31, 2013 were $5.4 million, compared to $4.9 million for the three months ended March&nbsp;31, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss
attributable to Arrowhead for the three months ended March&nbsp;31, 2013 was $6.8 million, or $0.41 per share based on 16.5&nbsp;million weighted average shares outstanding. This compares with a net loss attributable to Arrowhead of $5.3 million, or
$0.50 per share based on 10.7&nbsp;million weighted average shares outstanding, for the three months ended March&nbsp;31, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used
in operating activities for the first six months of fiscal 2013 were $8.3 million, compared with $6.9 million in the prior year period. Increased operating expenses and cash used in operating activities reflect pre-clinical requirements and final
IND-enabling steps, including GMP manufacturing and GLP toxicology, for the HBV program. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The company&#146;s cash position was $3.3 million at March&nbsp;31, 2013, compared to $3.4 million at
September&nbsp;30, 2012. During the first half of the fiscal year, cash outlays for research and development were $6.1 million, and cash used for general and administrative purposes were $2.7 million. Cash inflows during the first half of the fiscal
year included $7.1 million from the sale of equity securities in public offerings, $400,000 in revenue, and $1.2 million in proceeds related to the sale of our former subsidiary, Unidym. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Shares outstanding at March&nbsp;31, 2013, were 17.0&nbsp;million up 3.4&nbsp;million from 13.6&nbsp;million at September&nbsp;30, 2012. After giving effect to the $36 million offering closed last week,
common shares currently outstanding are 31.3&nbsp;million, excluding 5.4&nbsp;million shares reserved for the conversion of the preferred shares issued in the offering. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About Arrowhead Research Corporation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arrowhead Research Corporation is a clinical stage
targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to
cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For more information please visit <U>http://www.arrowheadresearch.com</U>, or follow us on Twitter <U>@ArrowRes</U>. To be added to the Company&#146;s
email list to receive news directly, please send an email to <U>ir@arrowres.com</U> </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement under the Private Securities
Litigation Reform Act: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This news release contains forward-looking statements within the meaning of the &#147;safe harbor&#148;
provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting
and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation&#146;s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form
10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
</I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contacts: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arrowhead
Research Corporation </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vince Anzalone, CFA </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">626-304-3400 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Trout Group </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Lauren Glaser </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">646-378-2972 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ir@arrowres.com </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"># # # </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g536117g79a24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g536117g79a24.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`4@"N`P$1``(1`0,1`?_$`,8``0``!@,!`0``````
M```````!!08'"`D"`PH$"P$!``$%`0$```````````````0!`@,%!@<($```
M!@$#`@(%!0D)$0`````!`@,$!08'`!$($@DA$S$4-#4V05$R,Q5Q(F(C4V,6
M%QAAL<%20T1D167P@9&A0G*2PI-4A=4F9I8W"A$``0,"!`,$!@8'!P4`````
M`0(#!``1(3$2!4$3!E%A,C-Q@9$B%`>AT4)28C3PL<$C8Q4U<I+"0U-$%H)S
MHR07_]H`#`,!``(1`Q$`/P#W\:4II2FE*:4II2FE*:4II2FE*ELI*LX=D[D'
M[A!JS8MU'3I=PLF@DB@D4QSJ***F(D0H%+Z3&`-_EU6PTZC@*PR'VXL=R2[?
MEMIN<A]*B![36$Y^;U?_`$F*V)39\U1$1(:5%B\-.@<H"45"1!$3L%$?,*/\
M\`>C8?3X:@F<TETMJOA7D+?SAVUW<0PF.X-O*K:R4%6&!-DK*<[VLK*LU8F7
M8S4<QE8QP@\82#5)VU<MUDEDE4E2=13%41.HF;8?`=A$`$!#4X64-0\)RKUJ
M)+9FQFID8A49T7![B+C*XOVXX5-=4J532E-*4TI32E-*4TI32E-*4TI32E-*
M4TI32E-*4TI32E-*5`1V#3,VXU4"]:P.X!EB_E9-,08]QOFFS-IMFE)W"S8Z
MQ3CW*%8<19E'+<M)FHW(SQ.'76='*1RL!$%1(0I`$0ZQUKI4W2DMM-K7;,@@
M>K&O"/G)O>\.0$[)T\W-<4JQ<4TPR^V0?LD.DI)%KD%)X5J4+1\A["?]GC/&
MX"`&VX+\/1*&_P!U$-AUI$N.E>LQUZCWBOFG_B&]J:6^G;IETK2#;:-MTX@$
MD`%`XXX#&];7>W_E3(39N^PS>L9YLKD='-G,U3;)D'$F.L6U6,CTS-RN*9%Q
MV-GRL0FMYBIW:/6@D)]U"@(](:W\.0^^`E;12D``9>ROI+Y/;OO4-D]*;K#E
MH*5%32W4,-(T\`$-.+"<,D@"V5A6T[4VO>J:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4II2FE*:4II2L<.4W)&E<6,2S65+J"[Q%H9&,@:\P6;I2UHL3\PI
ML8>+%R!D2J^6"BRBAP%-)%(QC>`>,25+9AIYSNNWX1>M3O>YM[1MKDU25N*`
ML$)%R;_57DZL&1.,.3[M+6&8KG,2Q76^619^Z!KD_'YG,K/3KT/+:,FJ-2\!
M6<KE102(``4O24H``:X>2N(\[S&_B`XM=[X\>X85\VRMHVS=]P+[[&\<U\WN
MTNR1?A8_:''U5O>8]L'#"G%53'RD7DU&W.I`F41>.+K%CDIO;$X844:*-J)%
M_898SU418&*#86X*&%783`!]=*WM3*XFE(7SK7N5*!]%KV^BO2H_RPV!/3:H
M"T2"Z?>)<-W;XD!1&9M8>RM#L3=^,>,;LQEV=:YC5F[T*RIND2N,GT(CN&LM
M=D?OV[ELM4Q`3M7K4R:J9P$#EW`0$!US27(L9PB\D.A6-B<P<:\RC;'L&T2^
M9#3-:EMJMK;24DD'.X%S?MKU?<3^3-.Y78CBLH4\'#`QG;F%L=;D%FJTQ6I^
M/$H.&$D+4I$#F<MSIN4E"%*FHBL42@&P@'<1)(FQDO)]TDX_IWU]*[-N8W6&
M)&DI5QO^G&LFM2ZVU-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E=*Y
MP3+UF,!"%W,<YC`0I"E*)C'.81`H$*4!$1'P#5R;8WI9-P5$BWTUYT><&9^?
M^1,X33'C]4;U7\/TT`@:^ZC5,>KHW-ZW,H,C<U23;UX<J+UP<R3+I*F(,R%,
M(`90P:UDIJ6ZK2Q?1Q'"N&WN=N;LHMPQ9I%QZ>^K\]M7'',JSW*?R5RGFK3&
MU"M(#&4^EV%C21):Y]X03+V%16`C3C]FUQ(G2CLN0QGI]]OQ(@*-$D(4''SE
MPJ_8(DMY\O3DC0G+`9]M;MRD)T@`%+L`B(>'AOOX_P"/6R)-R>)SKM@JXP)(
M-:5>Y7CCF)7K+7\H<6)VS/JQ.IGB;S2*\PI/_3LTV^_9VE%6?CB'&.G4Q%)S
MU+&$KPA3?RWAK9<66[^1L5=E<COD.:C_`-J`!I!Q%A:L;N%&8^X+C?.$`3/-
M.O-DP_:S!`6P9$^.T$JHHZ,3[.NB`0KYDL<(AP0I'8""@F9'.)2]12ZP0XDY
M%M0_=@XU!V21N;$L,/('()%^P=_JKT=I*D63*JF8ITS@!DU"&`Y%"&`!*H0Q
M=RF(<!W`0\!#QUN*[RNS2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5`1`
M/3X?=TI6I'NWY?S_``6!7.'.+]'EK=DC+0/(&SS<'-UF+<4#'QT`+,NQ&:GX
M=RE+VI-06+,R93]*(N%`$#$*.MWL\*/(?U3%+0R!<$))N;Y7K@.M-]E18GP.
MW\HR7"0H*6`4IM@<3<7/T5Y2<4=OKF3?<D4FEVN@/,7U2PV&/CK)D&SW.C)P
ME/@#*@>6FW8-K>Y<+J,V!#B@D0AC+.!(0`^^W#IY#6U,M+>8YCCR<!=)'LPQ
MKR"'&WF7-;CRW6&HI5=7[Q-CCF3JPKW7X/B<*8GQ_1,*XLLE0^PJ;!,Z]78>
M.LD-(2;Q-@V$[EZNDU>*.'LE(+`JZ<J`41.JH<X_+KAGVI))?<0L(OF4D`>L
MBOHC;7]I:9;@PGV5J2G)*TJ43Q-@2:OMJ-6VJR68X_#.2:3=L.Y3L-/&"N,"
M^K]D@I6QP\=()LI1L/EN4TG+M-RR?-A,1PV5Z0,FJ0AR^@-96&G]/-0A93?,
M`V]%ZUDV1M);7!GO,I*AX5+2DV[;$@UX3\Q]O7F#CW*-[I-(HCW*M*@;`]95
M+(E:N5%5A[;6SF\^'E4RN;<U60=J,5B$=(G3**3DAR>(%`==U&9VAZ,@O(4E
M0(N""#7SSN$7?(4I<6&J,MO'2H.I([L=5>I;M`Y;Y"2>#$,'<HJ-,5"]XC(V
MB:38IV>J\JM>\>BDI]EHB,//R[I28II4_4US'*4#M/5S[B;KUS.]P6(LCFPP
MKD*SP-A7K/0V^3)\,0=U2T);6"2E:3?T8XUN&`P&`!`0$!\0$!`0$/G#;6E!
M!%QB*]`R-CG4=5I32E-*4TI32E-*4TI32E-*4TI32E-*4TI7$X=0;;;AN&_W
M/EVU8LD(-J"UP3PK\PWO0'SS`]R'D\XSI'V=J^E<A/W..Y*4;OT(23Q(F1-#
M'?Z(NU"E9.X1I7R)IB5`QA2=`L50`5ZM_J3H5O8Y&P1U1^2IY+0"]5L#?'/C
M>OB+YE[9U$OJR4_+6\EM;AT!-\N!%N%LJU9_I0I_'5_VJH_Z^NT^#V_[L3VI
M^NO/OY9NG^I*]BJVZ]B&>%WW6>*2`J*_C)/(@"7K5$OWN+;F8!,`B)=O#Y=<
M1\Q(^WM]+/\`+0T'R18I(MF.PYUZ-\J84YCK6,Y(5(+0/&]L>WNK],@GT0_N
M^7]W7S`D@I%LK5]L6`RO;OK\UCO_`$X=EW7.2;<IU!Z&&)1Z04.3I`V+:J([
M``@`%$1U],?+EJ(YTNTF2F.H!9)U%-P.TWKXL^;L*>_UH^ZPN0EHBP(U6PS`
MMPK30-I5`/K%P``_*J^`?Z6N^,3;P"=,3VI^NO-D[9NEP.9*S_%6R_M`_K\L
M?<0XNKX!8V=Y/1.38-W<9&);R"\/%8O.N5'(RMO=ID,R:UYQ5#N4U`<&*514
MR92;JB0-<KUTC:&>G7OB!&2%-FVDBY/#3;&][5V_R[V_J,=5QOA%2"$NW-[V
MM8W)OV"^?U5^H8D7I#P#8/';T>C<=O1\@AKY/:20D`^Z`3AW7PK[C`LL\;@8
MUW:RU=32E-*4TI32E-*4TI7$3`'@.J*4$C4HV%4N-6GB:COIJ3VBJG"HZ`W%
MZ5#<-76-5L:AU!\P_P"#5@6";5;?TU'<-76JZQJ!_1Z!'Q#T:HHA*23E:K2D
M*L#?.J;FJ?4[,9$;)6*]81;=8MAGH6-EQ;>8("<&XR#9P*('$`WZ=M]M7,//
M,HT-K6$'&UR/U<:PN,17EE3C3:EC"Y`/[*D?ZIL5AZ<9X^_\,KG_`"W6?XF2
M<G%_WC]=6&%"_P!!K^XGZJ^R-QUCV%?H2D-0Z9$R37J%M(QE7A&#]N)R&3/Y
M#QHQ2<(B=,XE'I,&Y1$/0.K%/2EX*=66_NDDBB(4-*]:&&TK^\$I!_5>JT`?
M#6&X&>%2C@;"J,D\=T";?KR<W1:;,23GI\^1E*S"R+Y<$R@FGY[QVR6<*^6F
M`%+U&'8H``>&JM27T`MH4I+?<HX^JHSD5AY>M]MM:N!*`;>LU+_U58HWV_5E
M0/'P^"ZYMX_\-UE5*E`7*G;>D_76,1MN)P;9O_8'U54,'4:G6?/&MUBO5X'/
M3ZS]A0L;$>L]/T/6/L]LW\X"_)U;[:L6\X^$ZUK4!D"216=J-'CDJ9;;2HYZ
M4@'Z!51;@&J6-9;]Q]E1`=]4I01VTI3<-+4N*CI5:AU!H<,:H#?@:`8!]&K4
MJ2H7353@;&HZNI6(W.GE94>%'%?,?)&X&25;X[J#YW7H@ZA2+6B[R(DBJ556
M91.0RKF<L;QND8"[F(CUG]!#"$_:-L.];NQMB`2M9N0`3[HS/JK3=0;DWL^T
M/;DX0"A-AC:ZCD/;CZJTY=I[G?RB=<E)CA[SRS'2LL9+S!A*C\F\#6NHFIJ,
M;&M)>(,XR1@QT%-;MF1[%CY?=3H<`9R9-HY-UG3%,0[+JKIJ$UMAW7:&'4LQ
MW>2X%8$J!MK%\=).5^%<#T;U-N;F[#:]\?0M<AKG-V-[!6(1?(&P-QF"+8'"
MK_X([TB6;[S28AKPTSM!XOR!EW-6$8'-3>>I5KJK*^81BY&5L*-LB(!PI/5&
M%D",TTFSYZDFW,JX*4HGZ3[1)W2`@LJ6Y,8,E++;G+TJ"K.&P'9<<<:W$7K4
M2[K:AO?#<]3>O4FUTIU$Y7MC;N]%2/`W?3I>5(RGY`R)Q3S?A+`=\QGG3*%>
MSW*RE4O-)1AN/H2A;PRLJ%06<2-5DW+F'7;QJ;TJ9G[@4RH@8I^H+MPZ*>A+
M5%;E,O;D'&D!E(4%$N@$$$X87QJNV]=QIS293D=UG;RVXLNJ*2D!LD$&PS-J
MG%6[TOF-L$Y&RYPJS[@WC/R>MT)1\%\AK;8\>RT--3MR%8<=J7FE0$J[L^.H
M>]E2`[1VZ*N0J)O,,'0`F`]T<4<]B/+9>W&,"7&@E04E('O&YP.FK6^NU$,/
MR8;S6W239MTJ00HG(6`OC]&>-26^]^?"^/.)W[1LW@S*2E]9<D;]Q@L7&MC*
MUUUE&O7O&"$K+7E\[<)F/&+PL)5XXDD94A=C(."!N'WPA6/T)N,G<DP6W$<I
M3"'0[8Z++-@.V]ZK)Z_VV-M_QCB%\XOEKE:AKN/M96MZO2:E/.;NXMF&+<Q4
M/BBVL2^1F_;T><VF.=HIQ5G]6P[`6%-@&.F\W#3+>2+,66S*/TQ0;>2HB4A^
MHX"!1VS[)T<5[@RK>2$0Q/,<I-[J*0;D9>[]-1>H.LTL[:Z-HNY+,4N!22+(
MR-CAGC;AB<JJGBKW:;*XF.'V%.7?&_+V%;;R3PH2TX\SI9Y_&=DH6692D8V8
MW6ZV15G1)9:0IJ,S%E/))(N6B0HE<IIF3('B&#>.DD-)GSMI?;>;C3.7R4A0
M6$DV2;G#`X<;GV5?L_69'P$7=V'65RHFOG**=!4!<X#&^%[]^7&OHP7WMZ7R
M:O=3C<*\?9F7Q7=,EH8]@<HW/D#QRQY,R#4;`G7W5M8X8L-^+E-]%`J8RS1N
M1CZ\_3``12$Y@+K%N'1S^UQ%/S'OWR6@M2$M.**;B]BH"P-9MOZ\3NLKD[?$
M=5'YA0'"M`!L;7MB;53F=^^0QXS25R6S'Q0G(BET&UJP%HG:OR?XM7>WLH@D
MZ,*G9$,30.1%+^Z2.0Q'"C,&P.VZ9]E2D$IMLVV=%*W=M#D24D*<:*PE;3J#
M@+VQ'L.1JV=U\W`?6T_$=+;;@05I6@B][?15Y,J=UYL\RWD/CQQ0XR9NY3Y)
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MAW3<D5Z6BJK(KIT1)2ZL<>%9`ZL:X"S,W.[(ND!`.8=S;Z]2E=+1!.9C;7LK
M3\9:4J4I+RDD)^U9*SB0,NTFUJ\IC]5[@(3\C<=Y>9?;N$I+*5!2K7`*DC`7
MN">`QO6W[%W>1OV&>*'"5/F'B&P6#FWR@K5NGF.,8Y[1L*LEJ;5)R29L,F7N
M<R?.UBGXU:66"1:KHM%E04774-Y21"B!0Y*1T49^Z3QLBP=IB.I05V4JRU#P
M`)!42DW!P.797<M=9N[9M<0[PVM6[R!=+8(!4BQ(7<X6(!PSJYV0^][4\7TC
M"LI:^.DR7(V?<E7K'U"H,/R'XYSE42;T"(@I:8L5ISA'7E;%-7*M]O)(HL'3
MXKT3E$3E*4R8FA1^B)3TE^,7M/(1J)Y3V/<!I!]OLJ6_\P(D>.RZMETNO&P0
M+&W>56T^JJ^FN\90\:\7[URBSIA6;Q]7H'(53Q;0JM2\RX/SE+94N]Q;NEF$
M/$3.,;G*U>L"Q%F<SH\N[:%1;E,MXE#QBM](RI&\-[-%<"GEMZRI:%M)`[M>
M*SW)QK(KKB*G:U[K):4VTA>E*=:2I9XY#"PQQSX5/,:=T2Y9)HV9+@RXIMV;
MW%%5KEJ:UQOS!XF6%>SH3EC;PCYN\F8#(KV#H2<&S7,[4<S2S5LOY1FZ)SKB
M!1MF=,(A2&HSDA9<=64X,.X6XBX][U5=#ZQ5+9=?8BN<MM(4;K1C<<,,/75*
M8"[SE$RWR-KG&&[X-GL87Z]T*\7K'\G"9GP=G.H6`N/H9[/S\!)SV'KC9$ZI
M-#&1ZQVY'I"@L)=@VW`1S;CT=(A[>O<F7@ZPAT((+:VU7-L;+`P%Q6/;>NHN
MX;@C;GV'&7EME8)4E0L`2![O;;U<:H3`??0IV66%*OE^XH9PPQ@;(&/,\9&K
MV>)*5J=ZI+:+X\)RAKXQL[:GK.).J2*R\.LWCDWI$S/G`D*D!@-U!EF]$OQ'
M/A69++T\+0DM)"@H%P!0SPR5PK'`ZZCSD*D*C/-1`E2@LE)!""0;`#M!JZ>*
M^Y-F[DOCI7)&.>".?L;X*NF-<AW*A\E;]<\/,8UG#15'L<]4KJ[QNWL\G=#,
M)N2C6Y&J7JRHB#@BAP%+<=1I/3T+;GQ%D3F5SPXE*F0E>H'4`I.HV%QD:G1^
MJ-PW",9,:`^B$6R4NE:-)%C95AB1QK";@9WELRQ7&K@Y-\U./N9I>*Y,71AB
M&(YDLY3$[JD7?(EIMUBC*RH\Q]57\99JTP$K`69S&CDMO4E%"D.`[CN>H.B8
M;>[2F-FDM*7':*U-64%)2E(4JYR/;ZQ>M%L76TP;;&<WJ,]ID/!M+MTZ5*4K
M2,,#Z<^ZO3/U^'H#??;;?PWWVVWVUYH%@J*>RO4+X7K7]SEX`5;GI+\>(G*^
M0)AMA+"^3T\I7?!K:!8OJWG24CFGJE?AKO++/V[UE`1)5W/4@@D?U@')P$2B
M!1+T>Q=0/]/\]V$A/QSK10ET^)L',I';[,A7.]0=-QNH^0W.6KX1ES66QDO$
M8*((PL"..!.%\:QUR;V3N)CF]8"RSQ:@*]PPRU@/+,7DR-NV&J+#&&Y1S5NH
MUE:';XAV^9MG]=G&Z@IJ"!_,33.H0H""AM2(?5V[M1'H<]?Q3+Z`E042`"#?
M4,\:UT_HC:Y$EB5!O%>865`H%R18>[B<`+7%NTX5DWPKX*P/#'`F2<#PF0YN
M]QV1LJ9CRDO8I>#CH9[%.\P/#.WL,V8,7;ILX:00CTHJG.4ZP?2`-0MYWI>[
M[@F>IL-K2VA-@20=&1QMG:MGLW3[>T0'8"7"XAQQ2KD6MJ2$D9F^5\\SP&%4
M_P`:NW)C'!'`E7M^6JS3.7L6RM<R?4K/-S,<SK,S/064IRP3,LB#>(<NF\:Z
MCPGS)MUDSF,4R1%!#?PUFW7J*5N6_GJ%I(8E<Q"P`20"V``,;&QM6+;.F(>W
M[!_QY:B[$+;B5$@`GF&Y-AQ'"L1:EV8I,[+CUB_.'-G-&>N*_%FZ5R\8<X[V
M"CX^JR)).C'5#'S'(61J\U"SWJ%IC<_DMD%"-0.CN0P@7PUMG^L`LR9$6&VQ
MN<I)#CP6I1(4+*`2187K2,]#.I5&9ES''MKB*!;9*$I`(-P2H*OAZ[U<QMV=
ML%I\_<@\Y9.WV"88Y!B;FJ\X]OHJ.-C9AD3(U#8XUOF3FKGU@[LU@LU3;K(K
ME%`/QCDY_,$0*`8?^9[DG9&MG:`0IHILZ"=12E6H)MV8#CPRJ2KH:`[O+F[+
MLM*BHALBR05"VJ]^%[CW<^-6>P7V),1X+XR<R..[#.=_MC[EW3F.,U<HV2OP
MKFRXNQ=7F+AC3:#5V(R"C>0A:R5VJ9,JRR15!Z?O"`0-2-QZWG;EN,6:II"$
M1G5.:`39:E6Q)MA:V&!S-8H'0D2!MTO;T.*698L5Z<4IN#8#4;@D"^*>X"LH
M;;VS:5<KMV\;9+Y,GUFG`&BV>A1U>4K42K'Y=B;7BV(Q9)FLZXOR+5\3Q<6*
M_0T!8!.L8F^P`.M>UU*\Q'GLM-)2Y.<2LJU&[>E>NP%L<>)J6[THQ(>@?$*<
M6U!:4@)*19=TZ;J-\,.`O6*V$.QK3^-U\J,AA[/;5EBNE9&)>X/']\XN\=LA
MW9DQ//%G'%689[F*TWR<P;H^*+!\1;UZ-)TF1/U$*.MG+ZV<G,*^*8O,4V$%
M:75I!L+7*`-)]M:F-\OX\22%1WWTQDK*@D(3;$WMJO<^RK%SO_SG5-SBO)6!
MJMRN>PF)<C6:RV-<D]Q;P%=<OQ(V6PIV1=HWSW),V625A:O4")D5!RD<6X&3
M$.DY@&6U\PY:)#4MUA*Y#4<-`EQ8]T`VN`--Q<VN#6%7R\;4EQDR7_AW'^80
M6TG'#"^J]L!69EH[3<I"97GLU\8^8>6.,60LCXEQOB7.`PE#QQD6H9:88NIS
M.DUJQOJK=V"Y*[9"0K,"'69N>D1,.Q0$QC&U375@<B(A[K%1+:96I3.I:D\O
M4HJ(&D8BYXULU=%AN2Y(VF0]%6ZT$.:4)4%V2$WQ.9M<CMK+O@!PWA>!'%VD
M\98&_2^2XVF2MSE$KA.P\?`2<BK<[5*VIRFM%QCEVR;E9+RID2=)QZBD`1V$
M=M:3?-U7O>YJW)Q`;6H#W0;C``9G'A6^V#8CL.UC;$N%T:E**E#2;JSP!/ZZ
MQHPGVC<(XUX19RX-WVTRN8L=YUR%E+(DQ8)VOQ$!/UV5R.\823%6OE8.7J+:
M2H\M&(NHYYU@<5B!UEZ=RCMMQZMW&?O;6^-W9>:2D!*5'2=)OCE@<K5JH71N
MWQMC=V<I+B7KW6I"=0ND)N,3B+7SSRM5GL@]D^!RIC+BW%7_`)-W.WYUXD5Z
M<H>/<^V[%F-+P-JQK+&`K&FY1Q9>T+12KL%?:D33:/SBBZ`2>8814$3:GQ^N
M7XTF6J-'2WM\UU+CC27%I_>)S4'$V4-1Q-NVV50)O0K&Y1X[<Q]:Y<7!MP)`
M/+Q`;TZB"$WP4221@:JY?M47\V$JKA>-Y2T*,;0-]MUXE)(O`OBBZ@K`I8XZ
M"81S3]7[JNGJ,)(P01*IADVJ17K\CKRUS"1%,`B)ZGC"6]+7&>)>`%OBW\+$
M\3>X[B*DN=+S50VMO;FK;99-P2PV;]U]6%6CB?\`Y^\"2&'>1..LG9@N-RM_
M(3)V-,MN[_4Z!C3$T3CZY8BCI2-I;NE8GJ$.?';5L9M-NTY1!9JHG)HK"0X$
MVZM3%]?3Q/C3&&DAN.@I"5J+MP;8ZU`%)PS%0&OEUM_P3\>0\XX^^O5J*0-.
M>2+D<:^N:[&,+?,*9EPADWD@UE(3*2&/UXZ:QAQ5X\X)FJY/8ZM7Z4Q+Z=5Q
MO!1R61X1ZL'E.8F5`61OK2`138P83UHZ)K,U#+@+2BHI+ZU`W[+BZ?IK(.@6
MOA'8BI;NEQ(`(2D:0!;@<?7528=[+@8ZY,X>Y+VGDE'6N8PQ4,C4VO5.D<6\
M(X)AI1AD>GR51?NK"OBU*+/,OHU*0!=NJY36.44Q(`E*<V^2;US(F0'X'(LA
M]P+NIU:RFQ!L-0RP[J0?E_&A2V9@D+6XR@IQ0D:@01B0>_OK,#B]VZ<:<>."
M2W`>Q6B9R]C*5@\IUFSS<W&LZU+ST%E>=L<S,LQ;1#APA'K,4[&=%!9-03`*
M15!\?#6@G[]+F;Y_/60&I6M"@!B`4)2D8GMTUT6W=.1(.RJV19+L=25I)(L;
M+459#L)PJR^`.VKG#CY7(3#D%W!\Q7#B]6:?:\?06#+SB;$,HY:4N>JTU6X6
M`/E%E'1UQ6:U$\HDX:"7RS'!H1$VR8B`;#<>HH&XR#/5M[2-S*PHNAQ5RJX)
M.FUL3G6K@=-;C`8^!1N#JMO"2D-EM%@FUK`ZKY5)D^S]3TN'_"+B*&<K<,/P
MHSE2LWP=W"HP82U_?4NU6BTH5V9B1D190S%\K9S(G7;J*J$*B4P`(B(:'JI[
M^<3-X0TD/3&%MJ3J-@'$Z20;8X8UD7TBRYMD3:UNJY4.0AU)TC$H5J`(O@+\
M;D^FMQVW[^^N0"+**NVNQJ.KZ5#8!TO5;U'2J4TI7$2AL/W/W-5O:J6[S6&W
M,++5HQ9#8B"`O4%B^,O>6XZF7#(UB@F<]&U*N+U>TS1GIVTDZ:1B"CN4AVS8
MJK@_0`K"`??"74*8])96CDJ0EM2K%2A>PL>\#VUY/\TNI-SV&#MPA2FH,>7,
M+;TIQHNMQVTH4LK4C4G,I"+D@`J!X5BO*\G[FTAL7LFW*+'3BK6G.^3*#8N0
M*>,V3"`C*]4\=JVF`C!9R\BG5',B]G@*U/(-EA:KE4*FG^-(<-1#/6'$H+[1
M456OHPPX9V^FO/)?7F\QH6WH_GL-N#+W60RO</AB&TLH8#K`T*<"=2U7!5JL
M1889U3TARISVYIKEO0K\PRLX_:Q8X<K^1*)C^J.'MMHBV(U;V^/`PDC.L::X
MEF<TDHW]8,\32\M(R?BKL`FYLA35VEH>=Y^BR4VPM<9FU[X9UJ)7S2ZW=V%<
MG8Y36YLM=0&'\0RR+O,):#BRRP'#J<'WM5O37R0O*3E%;<>8C6K3M^^LN1.0
M&2*%Y;>D8_;9%;4NH4E_-M6-FJ,M:6]/J5Q93<8N1VBX>D4]6(78HF,7>Q,[
M<'0%-I2/>(Q3C;T7K`U\QOFA.V*"[`0MW<IF[O,I0EE"7A&0VA:.8TZXA#;E
MU&Y*\1D,*K.6SKR.ITCA>F9RRK4>/B]U+G*6F;Q:*E2I%9Q$U";J[?&D5(MT
M;"[IL//3$+-N%G239TKUF0#H$``X:N^,DI6TA]QIM2RJ]T<!E]JPK;.];_,#
M;I.V[/UEN$;8)<SGJ+KS*'4E+:TI:24AT)0M8)&"R";6-48[Y6\B).F8P&GV
M%U?7$]FCD?37MKQGC2IS4[>*'B.*<RE9L%8K=@GXNM'7D$4!%04'8BY(&R!3
M'$`U'&ZS.2'&PA9U+%PG`A)P(!-:;_ZE\Q)FU;:C;E.2ER-ZW2*MZ+$+JE1H
M2-33P;*TH25JN+ZR%>Z!C>W?^VIR">80Q5^AL2-[S1;%;O?I0U>QX\MIF.*:
ME899G5(:Y5BDKR;:FW?(B[="&7W5$D0Z(Z4,7='IU>[N4SX1E32!\2XHW]TV
MMZ`<.%94?.+KM71^U.P(;DOJN2)+[Z6XY=4U$8<4E"7H[2R69+Q`:*2H\MP*
M.(PJ\KW+V7\E9%XWOL4YD)6\:<BX.[3R4+)8J@I>7HRM#KD3(O:^Y?OG:+A:
M15F5W#5X#DA#MU$Q*0!Z=;!#TQ^2RIG2F&M!4JZ;JP&0-QZ,J[EWJ7K#?]^V
M.3T_N*F-BW@/+Y;L$E3264:N6XKF#22;I)('HJFK[R?R?%.#Q,ADNK8JA%^8
M61\+/\D3=1CW[&L4&J8U&TP`N$)1VUBCR$M8$P;BZ7.'6"O24.H`U&<GRDJ0
M"$H0IY22HBX``OE<8WK4=1_,'J."X&G)C&W05=02H2Y*V"L,1VF0XRZH%8'O
MK"D%1P5J%@+53++E+R$>PD_'XMN^.,X3$=RIH6*:7<75>1KU4OE3G,9?II.Q
M#AW77+]E&O0F"*L4Y)#S"M5"AYI#;&`<:9DMT#X=UE;G."2-!%TV-\;X6L/;
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M^2/#E]K+].SOKG=Y_H[OY'S'/S7D^%6=4TO\--O_`%G[2;VCX2^G_,_Z9JP^
M`>1XA^GI[.^M1(_HL?\`H?VO^QY7V>__``7K[HCV*+^!_>2GN/V'^5]U?VM\
M_P":ZM49\A7E>8?#EEQ[_P!M;:!G'_IOB7Y7E^6/*_C?>_AUW&]L4^#??"GL
M_O'V'_*_[B_*?T?;4R+F<O5^WNJ+)\V/_2?SB/,\7E#_`,OW?P5RN/LS7X)^
MM#XQ^H^I-]1^=_@U%>\UOR_M>+/_`*?VUEZ@_)?[#+_=>#QI\ON_;:NYE]7!
M_"GT'GNCV3Z!_<'YS\K^#OK&Q^4'E>,Y9>(Y=W;4F/FCRORLCR?!G_E_B^_W
MUSKWMLQ\+?36^'/>'M;GWK^=_C?G?,UD^VQX<SZ,OTO5D#Q2/R/E'R?,RX_A
M[?XFJN;+ZV-^&/:)3V+Z7I/[N_._[S^%K*UY+/\`9X9>K]OKJ2Q_M?+\U[PY
M>'_+[OO=UZELO[O?_`OO3^O_`&#T?UC_`&Q\_P"#MJK_`(4^#S#Z,N'?V]]0
M=V\<S^F>)'G>#P*\?X_\-J[H?V%K\#>\1]P^[OJC>P_VI_!U:BQ\T^3XQX<^
M/TUF8_)/?D_']CP>6,OXGW?PU5,7[PE/8_0T]G]J^J'WA^'^2_`WUE;\*O!Y
DARS]=38/YJ3Y6;67F>4/,_P]U3[5U;.FE*:4II2FE*:4K__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
